These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 6177959

  • 1. The emerging problem of plasma lipid changes during antihypertensive therapy.
    Johnson BF.
    J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S213-21. PubMed ID: 6177959
    [Abstract] [Full Text] [Related]

  • 2. Antihypertensive drugs and blood lipids: the Oslo study.
    Leren P, Eide I, Foss OP, Helgeland A, Hjermann I, Holme I, Kjeldsen SE, Lund-Larsen PG.
    J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S222-4. PubMed ID: 6177960
    [Abstract] [Full Text] [Related]

  • 3. [Changes in lipids and lipoproteins caused by the beta-blocking agents used as antihypertensives].
    Rouffy J, Chanu B, Bakir R, Sauvanet JP.
    J Pharmacol; 1983; 14 Suppl 2():183-99. PubMed ID: 6138467
    [Abstract] [Full Text] [Related]

  • 4. Antihypertensive therapy and the risk of coronary heart disease.
    Ames RP, Hill P.
    J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S206-12. PubMed ID: 6177958
    [Abstract] [Full Text] [Related]

  • 5. Do beta-blockers alter lipids and what are the consequences?
    Holtzman E, Rosenthal T, Goldbourt U, Segal P.
    J Cardiovasc Pharmacol; 1987; 10 Suppl 2():S86-92; discussion S93. PubMed ID: 2481177
    [Abstract] [Full Text] [Related]

  • 6. Plasma lipids during chronic antihypertensive therapy with different beta-blockers.
    Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, Malamani G, Corradi L.
    J Cardiovasc Pharmacol; 1989; 14 Suppl 7():S28-32. PubMed ID: 2481787
    [Abstract] [Full Text] [Related]

  • 7. Serum lipoproteins during treatment with antihypertensive drugs.
    Weidmann P, de Courten M, Ferrari P, Böhlen L.
    J Cardiovasc Pharmacol; 1993; 22 Suppl 6():S98-105. PubMed ID: 7508069
    [Abstract] [Full Text] [Related]

  • 8. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
    Oida K, Nakai T, Tamai T, Kutsumi Y, Kobayashi T, Hayashi T, Yamada S, Takeda R.
    Artery; 1982; 10(4):266-85. PubMed ID: 7181672
    [Abstract] [Full Text] [Related]

  • 9. [Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism)].
    Klein W.
    Z Kardiol; 1992 Jun; 81(6):295-302. PubMed ID: 1353932
    [Abstract] [Full Text] [Related]

  • 10. Coronary atherosclerosis and plasma lipoproteins: epidemiology and pathophysiologic considerations.
    Miller NE.
    J Cardiovasc Pharmacol; 1982 Jun; 4 Suppl 2():S190-5. PubMed ID: 6177955
    [Abstract] [Full Text] [Related]

  • 11. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [Abstract] [Full Text] [Related]

  • 12. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL, Lenz ML, Taylor AA.
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [Abstract] [Full Text] [Related]

  • 13. Risks for hyperlipidemia.
    Nestruck AC, Davignon J.
    Cardiol Clin; 1986 Feb; 4(1):47-56. PubMed ID: 2871933
    [Abstract] [Full Text] [Related]

  • 14. Effects of calcium antagonists and adrenergic antihypertensive drugs on plasma lipids and cellular cholesterol metabolism.
    Krone W, Müller-Wieland D, Nägele H, Behnke B, Greten H.
    J Cardiovasc Pharmacol; 1987 Feb; 10 Suppl 10():S199-202. PubMed ID: 2455133
    [Abstract] [Full Text] [Related]

  • 15. [High and low density lipoprotein abnormalities in coronary patients with LDL-C at target and uncontrolled HDL-C and triglycerides].
    Posadas-Romero C, Posadas-Sánchez R, Juárez-Rojas JG, Medina-Urrutia A, Jorge-Galarza E, Cardoso-Saldaña G, Caracas-Portilla N, Mendoza-Peŕez E.
    Arch Cardiol Mex; 2008 Feb; 78(1):30-9. PubMed ID: 18581711
    [Abstract] [Full Text] [Related]

  • 16. Antihypertensive therapy and lipids. Evidence, mechanisms, and implications.
    Weinberger MH.
    Arch Intern Med; 1985 Jun; 145(6):1102-5. PubMed ID: 2860883
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 18. Effect of mepindolol on serum lipids.
    Martignoni A, Perani G, Finardi G, Mastropasqua E, Fogari R.
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):543-5. PubMed ID: 7174157
    [Abstract] [Full Text] [Related]

  • 19. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
    Zanchetti A.
    Blood Press Suppl; 1995 Nov; 3():38-46. PubMed ID: 8535541
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
    Cubrilo-Turek M, Sertić J, Duraković Z.
    Acta Med Croatica; 2001 Nov; 55(4-5):161-7. PubMed ID: 12398019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.